Does Rallies show 13F holders for BSX?

Yes. Rallies tracks hedge fund and 13F ownership data for BSX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BSX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BSX. It does not provide personalized investment advice.

BSX (Boston Scientific) Stock Analysis - Hedge Fund Holdings

Boston Scientific (BSX) is a publicly traded Healthcare sector company. As of May 20, 2026, BSX trades at $56.63 with a market cap of $83.12B and a P/E ratio of 23.46. BSX moved -0.42% today. Year to date, BSX is -40.02%; over the trailing twelve months it is -46.74%. Its 52-week range spans $52.52 to $109.50. Analyst consensus is strong buy with an average price target of $89.12. Rallies surfaces BSX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BSX stock?

Hedge funds tracked by Rallies that own BSX include Farallon Capital, Maverick Capital, Viking Global, Temasek Holdings, and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Boston Scientific.

BSX Key Metrics

Key financial metrics for BSX
Metric	Value
Price	$56.63
Market Cap	$83.12B
P/E Ratio	23.46
EPS	$2.41
Dividend Yield	0.00%
52-Week High	$109.50
52-Week Low	$52.52
Volume	12.02M
Avg Volume	0
Revenue (TTM)	$20.61B
Net Income	$3.56B
Gross Margin	69.17%

Top Hedge Funds Holding BSX

Farallon Capital holds 7.47M shares of BSX, changed +0.42% as of Mar 31, 2026.
Maverick Capital holds 4.20M shares of BSX, changed +42.48% as of Mar 31, 2026.
Viking Global holds 2.51M shares of BSX, changed -4.99% as of Dec 31, 2025.
Temasek Holdings holds 2.40M shares of BSX, changed +15.27% as of Mar 31, 2026.
Orbimed Advisors holds 2.38M shares of BSX, changed -1.54% as of Mar 31, 2026.

Latest BSX News

Boston Scientific Coronary IVL Catheter Hits 93.3% Safety, 93.7% Effectiveness — May 19, 2026
Boston Scientific Invests $1.5B for 34% MiRus Stake with $3B TAVR Option — May 18, 2026
Boston Scientific Launches $2B Accelerated Buyback, Secures 30.4M Shares — May 18, 2026
Boston Scientific’s $1.5B Investment Secures 34% Stake and $3B Option in TAVR Valve — May 18, 2026
Penumbra’s Q1 Revenue Jumps 15.6% to $374.8 Million with $9.4M Acquisition Expense — May 6, 2026

Recent BSX Insider Trades

Mahoney Michael F sold 1.20K (~$112.87K) on Feb 2, 2026.
Mahoney Michael F sold 159.70K (~$14.93M) on Feb 2, 2026.
Butcher Arthur C sold 17.31K (~$1.76M) on Dec 1, 2025.

BSX Analyst Consensus

27 analysts cover BSX: 0 strong buy, 26 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.12.

Common questions about BSX

Who owns BSX stock?: Hedge funds tracked by Rallies that own BSX include Farallon Capital, Maverick Capital, Viking Global, Temasek Holdings, and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Boston Scientific.
Does Rallies show 13F holders for BSX?: Yes. Rallies tracks hedge fund and 13F ownership data for BSX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BSX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BSX. It does not provide personalized investment advice.